Clinical Microbiology and Infection最新文献

{"title":"Use of fluoroquinolones and risk of seizures: a population-based cohort study","authors":"Paraskevi Tassopoulou ,&nbsp;Annika Vivirito ,&nbsp;Philipp Heinemann ,&nbsp;Ava Rastegar ,&nbsp;Dirk Enders ,&nbsp;Antonios Douros","doi":"10.1016/j.cmi.2025.11.034","DOIUrl":"10.1016/j.cmi.2025.11.034","url":null,"abstract":"<div><h3>Objectives</h3><div>Fluoroquinolones can exert excitatory effects on the central nervous system. Our population-based cohort study assessed whether fluoroquinolones are associated with an increased risk of seizures.</div></div><div><h3>Methods</h3><div>We used German claims data from the InGef database (2016–2023) to assemble a cohort of patients initiating fluoroquinolones or amoxicillin. Patients were followed using a 30-day intention-to-treat approach. Inverse-probability-of-treatment-weighting based on propensity scores incorporating many potential confounders was used for confounding control. Cox proportional hazards models estimated hazard ratios (HRs) and 95% CIs of seizures associated with use of fluoroquinolones versus use of amoxicillin. Secondary analyses stratified by potential effect modifiers. All analyses were repeated using macrolides as an alternate comparator to control for residual confounding.</div></div><div><h3>Results</h3><div>Our cohort included 3 250 916 patients (mean age [standard deviation], 51 [18] years; 54% female) initiating treatment with fluoroquinolones or amoxicillin. Fluoroquinolones versus amoxicillin were not associated with the risk of seizures in the overall population (HR, 1.10; 95% CI, 0.995–1.23). There were increased risks among older adults (HR, 1.29; 95% CI, 1.07–1.47), patients without prior epilepsy (HR, 1.34; 95% CI, 1.11–1.61) and patients with chronic kidney disease (HR, 1.43; 95% CI, 1.11–1.85). Using macrolides as comparator led to no associations with the risk of seizures overall (HR, 0.89; 95% CI, 0.72–1.09) and in the different subgroups except for patients with chronic kidney disease (HR, 1.65; 95% CI, 1.03–2.63).</div></div><div><h3>Conclusions</h3><div>Our large cohort study showed that fluoroquinolones were not associated with the risk of seizures overall. An increased risk among patients with chronic kidney disease is possible.</div></div>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":"32 3","pages":"Pages 459-465"},"PeriodicalIF":8.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145676503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A supranational volunteer registry as a model for sustained vaccine research continuity and inclusive pandemic preparedness in Europe","authors":"Zoi Dorothea Pana ,&nbsp;Pauline Wipfler ,&nbsp;Jon Salmanton-García ,&nbsp;Ullrich Bethe ,&nbsp;Kerstin Albus ,&nbsp;Oliver A. Cornely","doi":"10.1016/j.cmi.2025.11.021","DOIUrl":"10.1016/j.cmi.2025.11.021","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":"32 3","pages":"Pages 496-497"},"PeriodicalIF":8.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145630721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Simultaneous detection of Schistosoma haematobium eggs and free miracidia in fresh urine: a diagnostic reminder for clinical microbiology laboratories in non-endemic settings","authors":"Alvaro Irigoyen-von-Sierakowski,&nbsp;Manuel Linares-Rufo,&nbsp;Carlos García-Bertolín,&nbsp;Juan Cuadros","doi":"10.1016/j.cmi.2025.08.007","DOIUrl":"10.1016/j.cmi.2025.08.007","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":"32 3","pages":"Pages 427-428"},"PeriodicalIF":8.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The emerging direct-to-consumer multiplex respiratory pathogen testing requires strengthened regulation","authors":"Tianxing Feng ,&nbsp;Yu Shi ,&nbsp;Kai Lin ,&nbsp;Yunlu Zhang ,&nbsp;Chouwen Zhu ,&nbsp;Mei Zeng","doi":"10.1016/j.cmi.2025.11.003","DOIUrl":"10.1016/j.cmi.2025.11.003","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":"32 3","pages":"Pages 350-352"},"PeriodicalIF":8.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145512093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Which trial do we need? Corticosteroid therapy in Lyme borreliosis–associated facial palsy: a double-blind placebo-controlled multicentre randomized trial","authors":"Daša Stupica ,&nbsp;Nataša Kejžar","doi":"10.1016/j.cmi.2025.11.007","DOIUrl":"10.1016/j.cmi.2025.11.007","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":"32 3","pages":"Pages 353-355"},"PeriodicalIF":8.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145530393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Next-generation sequencing improves detection of anaerobic and polymicrobial infections in pyogenic liver abscess","authors":"Ju Sun Song ,&nbsp;Young Kul Jung ,&nbsp;Solbi Kweon ,&nbsp;Seong-Hee Kang ,&nbsp;Min Jae Kim ,&nbsp;Jeong-Ju Yoo","doi":"10.1016/j.cmi.2025.11.018","DOIUrl":"10.1016/j.cmi.2025.11.018","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":"32 3","pages":"Pages 498-500"},"PeriodicalIF":8.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145630757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nobody leads by following, yet excellent editorship requires mentorship: reflections on Clinical Microbiology and Infection's first round of editorial fellows","authors":"Katharina Last ,&nbsp;Ili Margalit","doi":"10.1016/j.cmi.2025.11.024","DOIUrl":"10.1016/j.cmi.2025.11.024","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":"32 3","pages":"Pages 345-346"},"PeriodicalIF":8.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145630782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact and vaccine effectiveness of the 23-valent pneumococcal polysaccharide vaccine in adults aged 65 years or older in the Netherlands","authors":"F.A. Niessen ,&nbsp;A. Steens ,&nbsp;M.J. Knol ,&nbsp;R.H.H. Groenwold ,&nbsp;M.J.M. Bonten ,&nbsp;N.M. van Sorge ,&nbsp;H.E. de Melker ,&nbsp;C.H. van Werkhoven","doi":"10.1016/j.cmi.2025.09.027","DOIUrl":"10.1016/j.cmi.2025.09.027","url":null,"abstract":"<div><h3>Objectives</h3><div>The 23-valent pneumococcal polysaccharide vaccine (PPV23) was introduced into the Dutch national immunisation programme in 2020 to reduce invasive pneumococcal disease (IPD) and pneumococcal pneumonia among older adults. We evaluated the impact and vaccine effectiveness of PPV23 against vaccine-type IPD during the first 3 years after implementation, covering individuals born between 1941–1947 (70–73 years old in 2020), 1948–1952 (69–73 years old in 2021), and 1953–1956 (65–69 years old in 2022).</div></div><div><h3>Methods</h3><div>Impact and vaccine effectiveness (VE) were estimated using national surveillance data for IPD from the three season-years postimplementation (2020/21–2022/23). Vaccination programme impact, expressed as relative reduction of the vaccine-type IPD incidence in eligible age groups, was assessed using a regression discontinuity analysis, exploiting age-based vaccine eligibility. VE against vaccine-type IPD was estimated, stratified by year and birth cohort, with a complier average causal effect analysis.</div></div><div><h3>Results</h3><div>Regression discontinuity analysis showed a significant reduction in vaccine-type IPD incidence among vaccine-eligible adults, with estimated impacts of 43.9% (95% credible interval [CrI], 24.2; 60.9), 34.8% (95% CrI, 16.5; 50.6) and 32.1% (95% CrI 14.8; 46.9) for the 2020–2021, 2021–2022, and 2022–2023 seasons, respectively. Complier average causal effect analysis indicated statistically significant VE for all eligible cohorts, ranging from 48.1% to 73.1% (95% CrI ranging, 20.7–83.6).</div></div><div><h3>Conclusions</h3><div>The Dutch PPV23 immunisation programme led to a consistent and substantial reduction in vaccine-type IPD among older adults. Additionally, PPV23 vaccination provided a statistically significant protective effect against vaccine-type IPD among vaccinated individuals during the first 3 years after vaccination.</div></div>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":"32 3","pages":"Pages 440-445"},"PeriodicalIF":8.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145523088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Giants in infectious diseases: Prof. Jose M. Miró’s translational research in infective endocarditis","authors":"Juan M. Pericás ,&nbsp;Inma Lopez-Montesinos ,&nbsp;Juan Ambrosioni ,&nbsp;Guillermo L. Cuervo ,&nbsp;Cristina Garcia-de-la-Mària ,&nbsp;Marta Hernández-Meneses ,&nbsp;Carlos A. Mestres ,&nbsp;Asunción Moreno ,&nbsp;Jose M. Miro","doi":"10.1016/j.cmi.2025.11.017","DOIUrl":"10.1016/j.cmi.2025.11.017","url":null,"abstract":"","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":"32 3","pages":"Pages 356-361"},"PeriodicalIF":8.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145630728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Achieving global immunity against hepatitis A through universal vaccination: a position paper from the European Society of Clinical Microbiology and Infectious Diseases Study Group for Viral Hepatitis","authors":"Oana Săndulescu ,&nbsp;Stefania Mantovani ,&nbsp;Anne-Marie Roque-Afonso ,&nbsp;Gülsen Özkaya Sahin ,&nbsp;Asha K. Rajan ,&nbsp;Mustafa Altındiş ,&nbsp;Victor Daniel Miron ,&nbsp;Sertaç Küçükkaya ,&nbsp;Mario U. Mondelli ,&nbsp;ESGVH","doi":"10.1016/j.cmi.2025.11.026","DOIUrl":"10.1016/j.cmi.2025.11.026","url":null,"abstract":"<div><div>Hepatitis A virus (HAV) remains a preventable cause of acute viral hepatitis, with an estimated 159 million new infections and 39 000 deaths in 2019. Although improved care and hygiene reduced deaths, global incidence rose by approximately 4%, driven by increased symptomatic cases and population growth. The availability of safe and highly immunogenic vaccines and the absence of chronic carriage make HAV uniquely amenable to global eradication.</div></div><div><h3>Scope</h3><div>This position paper, developed by the European Society of Clinical Microbiology and Infectious Diseases Study Group for Viral Hepatitis, analysed current epidemiology, vaccine performance, economic evidence, and operational experience to articulate a time-bound strategic framework for eradicating HAV through universal childhood immunisation supplemented by targeted catch-up, outbreak-response, and high-risk group programmes.</div></div><div><h3>Methods</h3><div>A comprehensive literature search was conducted in PubMed databases from inception to May 2025. The search strategy incorporated explicit terms related to HAV and vaccine effectiveness, implementation, and public health outcomes. The methodology adhered to established standards for developing evidence-based recommendations that were evaluated and refined through expert panel discussions within the European Society of Clinical Microbiology and Infectious Diseases Study Group for Viral Hepatitis, ensuring methodological transparency, accuracy, and alignment with current scientific evidence.</div></div><div><h3>Questions addressed by the position paper and recommendations</h3><div>To evaluate vaccine effectiveness, the following primary outcomes were considered: HAV infection rates, seroconversion rates, long-term immunogenicity, safety outcomes, outbreak control effectiveness, cost-effectiveness, barriers to vaccine implementation, strategies to enhance vaccine availability and uptake, and overall public health impact. Drawing on lessons from countries that have reduced hepatitis A by &gt;95%, this document proposes policy actions to overcome barriers related to vaccine cost, production capacity, programme logistics, and vaccine hesitancy. The paper concludes that with concerted political commitment and incremental scale-up of vaccine supply, the global elimination of hepatitis A as a public health threat, and its eventual eradication, is achievable within a defined time frame.</div></div>","PeriodicalId":10444,"journal":{"name":"Clinical Microbiology and Infection","volume":"32 3","pages":"Pages 416-426"},"PeriodicalIF":8.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145647673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}